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Abstract: Pathogenic variants in the mitochondrial tyrosyl-tRNA synthetase gene (YARS2) were
associated with myopathy, lactic acidosis, and sideroblastic anemia (MLASA). However, patients
can present mitochondrial myopathy, with exercise intolerance and muscle weakness, leading from
mild to lethal phenotypes. Genes implicated in mtDNA replication were studied by Next Gener-
ation Sequencing (NGS) and whole exome sequence with the TruSeq Rapid Exome kit (Illumina,
San Diego, CA, USA). Mitochondrial protein translation was studied following the Sasarman and
Shoubridge protocol and oxygen consumption rates with Agilent Seahorse XF24 Analyzer Mi-
tostress Test, (Agilent, Santa Clara, CA, USA). We report two siblings with two novel compound
heterozygous pathogenic variants in YARS2 gene: a single nucleotide deletion in exon 1, c.314delG
(p.(Gly105Alafs*4)), which creates a premature stop codon in the amino acid 109, and a single nu-
cleotide change in exon 5 c.1391T>C (p.(Ile464Thr)), that cause a missense variant in amino acid 464.
We demonstrate the pathogenicity of these new variants associated with reduced YARS2 mRNA
transcript, reduced mitochondrial protein translation and dysfunctional organelle function. These
pathogenic variants are responsible for late onset MLASA, herein accompanied by pancreatic insuf-
ficiency, observed in both brothers, clinically considered as Pearson’s syndrome. Molecular study
of YARS2 gene should be considered in patients presenting Pearson’s syndrome characteristics and
MLASA related phenotypes.
Keywords: mitochondrial aminocyl-tRNA synthetase; novel pathogenic variant; Pearson’s syndrome
1. Introduction
Mitochondria are ubiquitous organelles that integrate various metabolic pathways
(oxidative phosphorylation (OXPHOS), fatty acid oxidation, Krebs cycle, urea cycle, glu-
coneogenesis and ketogenesis) [1] and are involved in different crucial functions for cells
(thermogenesis, biosynthesis of heme and iron–sulfur clusters (Fe–S), calcium homeostasis
and apoptosis) [2].
A particularity of these organelles is that mitochondrial protein synthesis and, thus,
mitochondrial function, is controlled by two different genomes: mitochondrial DNA
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(mtDNA) and nuclear DNA (nDNA). Mitochondrial DNA consists of 37 genes, of which
only 13 codify subunits of the OXPHOS system while 2 rRNA and 22 tRNA are coded for
their translation [3]. The other mitochondrial proteins are codified by nDNA, synthesized
in the cytosol and imported into the mitochondrion.
To maintain an adequate pool of mitochondrial proteins, mtDNA replication must be
continuous and highly effective. One of the key group proteins involved in mitochondrial
translation are the mitochondrial aminocyl-tRNA synthetases (aaRSs) [4]. Mitochondrial
aaRSs catalyze the attachment of the amino acids to their cognate tRNA in a reaction
known as aminoacylation of the tRNAs. Nuclear genes codify for all mitochondrial aaRSs.
Pathogenic variants in genes coding for mitochondrial aaRSs have recently been shown to
account for an increasing number of mitochondrial diseases, with phenotypic heterogeneity
and significant tissue specificity [5].
Inherited sideroblastic anemia has been associated with pathogenic variants in several
genes such as ABCB7, ALAS2, GLRX5, YARS2, PUS1, SLC25A38, TRNT1 and SLC19A2 [6],
but the phenotype is variable with overlapping clinical presentations. MLASA syndrome
(myopathy, lactic acidosis and sideroblastic anemia) was first described as associated
with PUS1 [7] pathogenic variants, and later in patients with similar phenotype YARS2
pathogenic variants [8]. Moreover, heteroplasmic m.8969G>A variant in MT-ATP6 gene
and LARS2 pathogenic variants were found in MLASA patients [9,10].
YARS2 encodes the mitochondrial tyrosyl-tRNA synthetase protein, which is involved
in the tyrosine binding to its analogous tRNA in the mitochondrion. It is encoded in
chromosome 12p11.21 and pathogenic variants in this gene (OMIM#610957) have been as-
sociated with disease in a recessive mode of inherence (homozygous or compound heterozy-
gous). Pathogenic variants have been described as previously associated with infantile-
to childhood-onset autosomal recessive MLASA2 syndrome (OMIM#613561) [8,11] with
mitochondrial respiratory chain (MRC) deficiency [12]. Penetrance for the most common
pathogenic variant is complete, but a wide phenotypic variability has been evidenced.
Within the variable phenotype, cardiomyopathy, diarrhea, hepatosplenomegaly and ovar-
ian failure have been described (HGMD database) [8,11–17]. It has been hypothesized that
mitochondrial mtDNA haplotype background may influence phenotypic expression, and
haplotype H was associated with slower progression and less severe phenotype in YARS2
patients [12,13], but further evidence is needed to confirm this association.
In this study, we present a family with two affected brothers (P1 and P2) with late-
onset MLASA and pancreatic insufficiency, previously clinically diagnosed as Pearson’s
syndrome. Multiple mtDNA deletions were previously reported in these patients and their
unaffected mother (P3), accompanied by multiple enzymatic respiratory chain deficiencies
in the case of both siblings [18]. Current examination by whole exome sequencing (WES)
revealed that P1 and P2 were compound heterozygous for YARS2 potential pathogenic
variants.
2. Materials and Methods
This study was carried out by the tenets of the Declaration of Helsinki and was
approved by the local bioethics committee of our hospital. Informed consent was obtained
from the patients, and age-matched controls. Exclusion criteria of age-matched controls
were the presence of any concomitant disease, contact with mitochondrial toxics and family
history of mitochondrial disease or drug abuse.
2.1. Source of Samples
Blood sample and fibroblasts were obtained from P1. Muscle biopsy was performed
in P2 following standardized procedures and was immediately cryopreserved at −80 ◦C.
Mouth swab was taken from P3.
Fibroblasts were obtained from P1 and matched controls by a skin punch biopsy, as
previously reported [19,20] and were grown in 25 mM glucose DMEM medium (Gibco, Life
Technologies, Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine
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serum and 1% penicillin-streptomycin at 37 ◦C, in a humidified 5% CO2 air incubator, until
80% optimal confluence was reached.
2.2. DNA and RNA Isolation
Total DNA was obtained by standard phenol chloroform procedure from healthy
controls and patients’ samples; blood and fibroblasts (P1), muscle biopsy (P2) and mouth
swab (P3). Total RNA was isolated from P1 and control fibroblasts with RNAeasy mini kit
(Qiagen, Venlo, The Netherlands) and cDNA was obtained by retro-transcription performed
with High-capacity cDNA Reverse transcription kit (Applied Biosystems, Foster City, CA,
USA), as previously reported [19].
2.3. mtDNA Maintenance Genes Custom Panel
Exonic and the flanking intronic regions of 17 genes (DGUOK, DNA2, FBXL4, MGME1,
MNF2, MPV17, OPA1, POLG, POLG2, RNASEH1, RRM2B, SLC25A4, SPG7, SUCLA2, SU-
CLG1, TK2 and TWNK) implicated in mtDNA replication and maintenance were studied
by Next Generation Sequencing, using a previous designed panel with GeneRead Cus-
tom Panel V2 (Qiagen) technology. Briefly, 20 ng of total DNA were amplified by the
panel. The resultant amplicons were purified and used to prepare individual libraries
with NEBNext Ultra II DNA for Illumina Library Prep Kit (New England Biolabs, Ipswich,
MA, USA). Independent libraries were quantified with Qubit® dsDNA HS Assay Kit (Life
Technologies), normalized to 4 nM concentration and pooled. The pooled libraries were
sequenced into MiSeq platform (Illumina, San Diego, CA, USA). Data analyses were per-
formed with GeneRead Targeted Enrichment Exon Panel Data Analysis (Qiagen, Venlo,
NL, USA) software and results were annotated with a laboratory pipeline.
2.4. Whole Mitochondrial mtDNA Sequencing
In patient’s muscle DNA (P2), whole mitochondrial genome was amplified in a single
amplicon by long- range PCR using the Takara LA PCR kit as previously described [20].
10–20 ng of DNA is needed per reaction. Qubit 2.0 Fluorometer (Thermo Fisher Scientific,
Waltham, MA, USA) was used for quantifying the amplicons and normalized each sample
to 0.2 ng/µL. Amplicons were used for sample library preparation with Nextera XT DNA
Sample Preparation kit (Illumina, San Diego, CA, USA), following the manufacturer’s
instructions. 1 ng of amplified mtDNA is needed to prepare each library consisting
of fragments of 150 pb. PCR amplicons were cleaned up with Ampure beads XT, and
the libraries were normalized and pooled. The pooled libraries were loaded into the
MiSeq Reagent kit V2 (300 cycles and 2 × 150 chemistries) (Illumina, San Diego, CA,
USA) and sequencing proceeded in the MiSeq platform (Illumina, San Diego, CA, USA).
In general, 40 libraries were multiplexed to obtain 5000X medium coverage. On-board
software converted raw data to BAM/BAI and VCF files using GATK tools. These files
were analysed by MiSeq Reporter Software.
2.5. Whole Exome Sequence
Whole exome was studied with TruSeq methodology in patient’s muscle DNA (P2).
The exonic and the flanking intronic regions were captured and the DNA libraries were
prepared with the TruSeq Rapid Exome kit (Illumina, San Diego, CA, USA), following
manufacturer’s specifications. The sequencing was carried out in a NextSeq platform, data
analyses were performed with DNANexus platform and we used a laboratory pipeline to
variant annotation. The candidate pathogenic variants found were confirmed by Sanger
sequencing. The two candidate variants found in YARS2 gene were also analysed by Sanger
sequencing in mother buccal mucosal DNA (P3) and in blood and fibroblast DNA and
cDNA extracted from P1.
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2.6. Expression of YARS2 mRNA by Real Time PCR (qPCR)
Quantification of YARS2 gene expression was performed with the resultant fibrob-
last cDNA by qPCR in an ABI Prism 7900HT Sequence Detection System, with TaqMan
Universal Master Mix, in a 12.5 µL reaction, using two different TaqMan YARS2 gene
expression assays (Hs01126899_m1 and Hs01126901_m1, Thermo Fisher). PPIA assay
(Hs99999904_m1, Thermo Fisher Scientific) was performed to normalize the results and
used as endogenous control. Relative gene expression quantification was calculated with
Ct data by RQ Manager 1.2.1 Software (Thermo Fisher Scientific). Every analysis was
performed in quadruplicate.
2.7. Mitochondrial Translation
Mitochondrial protein translation was studied in fibroblasts (P1 and 4 controls) three
times, following the Sasarman and Shoubridge protocol [21]. We seeded a 60 mm culture
plate per cell line of fibroblasts until they reached 80–90% confluence. Cells were washed
twice with PBS 1X and incubated for 30 min with 2 mL of labelling media (DMEM without
methionine and cysteine, 1X GlutaMax, 110 mg/L sodium pyruvate), equilibrated previ-
ously for 30 min to 5% CO2 and 37 ◦C. One hundred µL of 2 mg/mL emetine was added
and incubated for 5 min followed by 60 min of incubation with 400 µCi of EasyTag labelling
mixture. Next, the media was removed and replaced by 5 mL of equilibrated DMEM High
glucose media with 10% FBS for 10 min. Cells were washed 3 times with PBS and, using a
cell lifter, cells were collected by 750 µL to cold PBS 1X. Cells were centrifuged at 1500× g
for 10 min at 4 ◦C, the supernatant was removed, and the pellet was resuspended in 100 µL
cold PBS. We determined the protein concentration by BCA Protein Assay Kit and the
volume corresponding at 100 µg of protein was centrifuged at 20,000× g for 20 min at
4 ◦C. The resultant pellet was resuspended in 50 µL of loading buffer (Tris 100 mM pH 6.8,
SDS 4%, 20% glycerol, DTT 1M, 1% bromophenol blue) and sonicated for 40 min. Finally,
samples were centrifuged for 10 min at 20,000× g.
2.8. SDS Page and Signal Quantification
Samples were loaded in a 20 cm long and 1 mm thick 17% acrylamide/bisacrylamide
gel. Electrophoresis was carried out at 100 V for 16 h. The gel was fixed with a solution
of acetic acid and methanol (acetic acid 10%, methanol 45%, water 45%), dyed with
Coomassie blue (acetic acid 10%, methanol 45%, water 44.9%, 0.1% Coomassie blue) and
dried. The labeled bands were visualized by autoradiography exposing a film for 5 days.
Quantification was performed by measuring the density value of mitochondrial protein
content and correcting it with the total protein load.
2.9. Functional Mitochondrial Characterization
In order to assess mitochondrial performance, fibroblasts were exposed for 24 h
to 10 mM galactose media, where cells are forced to rely on oxidative phosphorylation for
ATP production. Fibroblasts were harvested with 2.5% trypsin, (Gibco, Life Technologies™)
and centrifuged at 500× g for 8 min. Experiments were performed in parallel with P1 and
controls fibroblasts at the same passage.
2.10. Mitochondrial Oxygen Consumption
Oxygen consumption rates (OCRs) were measured with Agilent Seahorse XF24 An-
alyzer Mitostress Test (Seahorse Bioscience, Agilent, Santa Clara, CA, USA), according
to manufacturer’s protocol. Briefly, 30,000–35,000 fibroblasts/well were seeded in qua-
druplicate in customized 24-well Seahorse cell culture plates and incubated overnight in
250 µL of 10 mM galactose medium. Growth medium was then removed, and wells were
washed once with Seahorse XF Base Medium (Seahorse Bioscience) containing 10 mM
Galactose, 1 mM Sodium Pyruvate and 1 mM Glutamine. Plates were incubated in this
media for 30 min at 37 ◦C without CO2. The bioenergetic profile was measured obtaining
the OCRs under basal condition and after the addition of oligomycin, carbonyl cyanide-4-
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(trifluoromethoxy) phenylhydrazone (FCCP) and rotenone-antimycin (all reagents from
Sigma-Aldrich). OCR values were normalized to total cell protein content and reported as
pmol/min·µg protein.
Bioenergetic Health Index (BHI) was calculated to assess the mitochondrial profile of
the subjects studied by the equation described by Chacko et al. [22].
2.11. Cell Growth
Cell growth rate was determined through cell counting with a Neubauer chamber
at the times of seeding and harvesting the cells in galactose media at 4, 7 and 10 days
of growth. Results are reported as fold-change of growth from day one to ten of the
experiment.
2.12. Mitochondrial DNA Deletion Study
Total DNA from fibroblasts was extracted using the standard phenol–chloroform ex-
traction procedure. The assessment of mtDNA deletions was performed by long-range PCR
using Phusion High-Fidelity PCR Master Mix with GC Buffer (F-532L, ThermoFisher Scien-
tific, Waltham, MA, USA) and the following primers: forward 5′-TTAGCAAGGGAACTACT
CCCA-3′ and reverse 5′-CGGATACAGTTCACTTTAGCTACCCCCAAGTG-3′. The PCR
products were electrophoresed in a 0.8% agarose gel, stained with SYBR safe to analyze mi-
tochondrial DNA integrity, and run in parallel with positive and negative quality controls.
2.13. Statistical Analysis
Results were expressed as mean ± standard error mean (SEM). Statistical analysis was
performed through using the non-parametric Kruskal-Wallis test and the Mann–Whitney
U test, with SPSS version 22 (IBM, Armonk, NY, USA). Significance was set at p < 0.05.
3. Results
3.1. Clinical Data of Case Reports
Two brothers were born after a term pregnancy to unrelated healthy parents. From in-
fancy, they presented easy fatigability. P1 had permanent basal hyperlacticaemia (68–80 mg/dL;
normal 5–22), leukopenia, anemia and signs of pancreatic insufficiency. Bone marrow ex-
amination revealed vacuolization of early and late erythroid and myeloid cell precursors,
with more than 15% ringed sideroblasts. He was transfusion dependent for four years.
Neurological examination revealed a mild but progressive proximal muscle weakness, and
electromyography (EMG) disclosed a generalized myopathic pattern. P1 was clinically
diagnosed with Pearson’s syndrome at 23 years old, started treatment with L-carnitine
and CoQ10 and is currently stable at 48 years old. P2 disclosed very similar findings,
including ringed sideroblasts on bone marrow examination although P2 never required
transfusions. Pancreatic insufficiency, manifested as steatorrheic feces, was also confirmed
and consequently, he was diagnosed with Pearson’s syndrome at 23 years old. Later, P2
developed a dysembryo-plastic neuroepithelial tumor (DNET) in the brain not requiring
specific treatment since the only clinical manifestation was a mild seizure and the tumor
size did not increase over time. He died at 49 years old due to respiratory failure and
refractory acidosis. Previous evaluation of P1, P2 and their mother (P3) revealed multiple
mtDNA deletions and MRC deficiencies in both siblings [18].
3.2. Genetic and Molecular Findings Revealed Two Potentially Pathogenic Variants in YARS2 Gene
Based on the previous results reported for multiple mtDNA deletions in muscle [18],
P2 was studied genetically with an mtDNA maintenance gene custom panel. No pathogenic
variants were found in muscle DNA from P2 in the 17 genes studied with the custom panel,
that includes the majority of genes associated with pathogenicity involved in mtDNA
depletion and multiple deletion syndromes. Whole mtDNA was sequenced by NGS
in muscle DNA from patient P2 and no pathogenic variants were found. In addition,
mtDNA integrity was analyzed in DNA from fibroblasts form patient P1, and non-multiple
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or single deletions were found. However, whole exome sequencing was performed in
P2 DNA sample, and two potentially pathogenic heterozygous variants in YARS2 gene
were found, a single nucleotide deletion in exon 1, c.314delG (p.(Gly105Alafs*4)), which
creates a premature stop codon in the amino acid 109, and a single nucleotide change
in exon 5 c.1391T>C (p.(Ile464Thr)), that causes a missense variant (NM_001040436 and
NP_001035526).
Sanger sequencing confirmed both variants in P2, and evidenced the same variants
in P1 DNA sample. In mother’s DNA sample only the variant c.1391T>C (p.(Ile464Thr))
was found, indicating the maternal inheritance of the missense variant in both P1 and P2
brothers.
The c.314delG variant is a frame-shift variant affecting YARS2 gene, which is a known
mechanism of disease, associated with myopathy, lactic acidosis, and sideroblastic anemia 2.
This variant has been reported in population database as gnomAD Exomes with a frequency
of 0.000004, less than the 0.0001 threshold for recessive gene YARS2. This variant is not
found in gnomAD Genomes database nor in databases associated with pathology (ClinVar,
HGMD). This variant is located in the catalytic domain and the amino acid conservation
study indicates that glycine at the position 105 in YARS2 protein is a conserved amino acid
(Figure 1). According to ACMG guidelines [23,24] this variant is classified as pathogenic
(PVS1, PM2, PP3). The c.1391T>C variant predicts the change of isoleucine to threonine
in the amino acid 464 of the protein. This variant has not been reported in population
database as gnomAD Genomes, gnomAD Exomes database nor in databases associated
to pathology (ClinVar, HGMD). In silico pathogenicity predictors classify this variant as
deleterious (DANN, FATHMM-MKL, MutationAssessor, MutationTaster, PrimateAI and
SIFT). This variant is located in the S4-like region and the isoleucine residue located at
the site of the missense variant is partially conserved in mammals and birds (Figure 1).
According to ACMG guidelines, this variant is classified as “likely pathogenic” (PM2, PM3,
PP2, PP3) [23,24].
3.3. YARS2 mRNA Expression in Fibroblasts from Patient P1 Were Consistent with Our Genetic
Findings
In order to investigate if the two candidate YARS2 variants can affect YARS2 mRNA
expression, TaqMan assays located in exon 1-2 and 3-4 boundaries of YARS2 gene were
performed in cDNA obtained from total RNA of P1. We observed a reduction of 30% in
P1 YARS2 mRNA content comparing with the mean levels of five controls (Figure 2A)
with both TaqMan assays (p = 0.003 and p = 0.015 by using Hs01126899 and Hs01126901,
respectively). Moreover, we analyzed by Sanger sequencing the presence of the variants
in the same cDNA, electropherogram of P1 cDNA sample showed a low-height peaks
started coincident with the location of the single nucleotide deletion pathogenic variant
(c.314delG) (Figure 2B) while the other candidate causative variant c.1391T>C showed a
high-height peak and wild type variant was difficult to distinguish from background noise,
suggesting the presence of nonsense-mediated mRNA decay (NMD) that magnifying the
proportion of the missense allele vs. the truncated one. Accordingly, we observed a partial
reduction in the expression of YARS2 in fibroblasts of P1. This observation indicates that
the c.314delG frameshift variant should have been eliminated by nonsense mediated decay,
and the 70% remaining levels correspond to the expression of the missense allele (probably
a little overexpressed due to the absence of the other allelic counterpart). Moreover, these
results confirm that the two variants are located in trans.
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3.4. Decreased Mitochondrial Translation in Patient P1
To assess YARS2 functionality we performed a mitochondrial translation assay in
fibroblasts. We observed an 80% of reduction in the total content of mitochondrial protein
translation in fibroblasts from P1, compared with control fibroblasts (Figure 3).
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Figure 3. Mitochondrial translation assay. (A) Mitoch ri l translation assay showing decreased quantity of the proteins
synthesized by mitoch ndrial ribosomes in ti t 1 (P1) compared to c ntrols (C1-C4). Left: Coomassie gel showing
the total amount of protein. Right: Exposed autoradiography film showing the mitochondrial bands. (B) Quantification
of mitochondrial translation. Mitochondrial translation assays were performed in three independent studies in 4 control
fibroblast cell lines and in the atient’s fibroblasts. The results show the quantification of mitochondrial translation of the
patient fibroblasts with respect to the mean of the control fibroblasts (n = 4).
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3.5. Functional Mitochondrial Characterization Revealed Associated Deficiencies in Mitochondrial
Function in Patient P1
To assess if the reduction in mitochondrial protein synthesis was further translated
into deficiencies in mitochondrial function, we measured mitochondrial oxygen consump-
tion in fibroblasts from P1 and in fibroblasts from 2 controls. Mitochondrial respiration
rate of fibroblasts from P1 demonstrated a deficient OXPHOS activity, evidenced by de-
creased ATP-linked respiration (C 3.9090 ± 0.35 vs. P1: 2.4467 ± 0.5 pmol/min*µg protein;
p = 0.05), maximal respiratory levels (C 19.93 ± 1.61 vs. P1: 6.3217 ± 1.36 pmol/min*µg
protein; p = 0.009) and spare capacity (C 9.834 ± 1.109 vs. P1: 2.8159 ± 0.82 pmol/min*µg
protein; p = 0.009), accompanied by a significantly decreased BHI (C 7.3350 ± 0.72 vs.
P1: 2.1250 ± 0.44 pmol/min*µg protein; p = 0.029) (Figure 4) confirming deficiencies in
mitochondrial function in patient P1.
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affecting distinct molecular  targets  [26]. YARS2 encodes  the mitochondrial  tyrosyl‐tRNA 
Figure 4. Mitochondrial functional characterization, overall cell health and growth rates. (A) Oxygen
consumption rate was slightly decreased in fibrobl st from patient P1. (B) The alteration is made
more evident after MRC CV inhibition by ligomycin (ATP-linked respiration). (C) Decrease in
posterior mitochondrial uncoupling (maximal respiration capacity) and (D) spare capacity. (E) BHI is
significantly reduced and (F) growth rate in galactose media was significantly affected in the patient
P1 with YARS2 candidate variants.
3.6. Cell Growth Was Significantly R duced in Fibroblasts from Patient P1
To further assess the effect of this YARS2 causative variants in overall cell health
performance, cell growth was measured in conditions where cell growth depends on
OXPHOS function. As shown in Figure 4F, cell growth was significantly decreased in
fibroblasts from patient P1 in galactose media compared with controls (Fold-Change C:
7.5 ± 1.23 vs. P1: 1.880± 1.1, p = 0.008) indicating that the variants in YARS2 gene found in
patient P1 are associated with both mitochondrial dysfunction and decreased cell growth.
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4. Discussion
Pearson’s syndrome presents with infantile sideroblastic anemia and exocrine pancre-
atic insufficiency, associated to a large-scale single mtDNA deletion [24,25]. Sideroblastic
anemias are rare errors of metabolism caused by mutations of genes involved in heme
synthesis, alterations in iron–sulfur cluster biogenesis and transportation, defects in MRC
protein synthesis and, consequently, energy production. To date, six genes have been dis-
covered that may cause sideroblastic anemia: PUS1, YARS2, LARS2, TNRNT1, NDUFB11
and MT-ATP6. Moreover, pathogenic variants in PUS1, YARS2 and MT-ATP6 were as-
sociated with MLASA syndrome, and consistently PUS1 and YARS2 are responsible for
an almost identical clinical syndrome MLASA by altering the MRC protein synthesis
by affecting distinct molecular targets [26]. YARS2 encodes the mitochondrial tyrosyl-
tRNA synthetase protein, and pathogenic variants in this gene have been associated with
MLASA2 with a variable phenotype presentation. The siblings that are presented in this
work were initially diagnosed with Pearson’s syndrome; however, mtDNA study did not
evidence a single large-scale deletion, though multiple deletions were observed [18]. For
this reason, a panel of genes related to the mtDNA maintenance was analyzed in P2 but no
pathogenic variants were found. Previously to the WES approach, whole mtDNA NGS
sequencing was performed in P2 to discard any pathogenic variants in mtDNA as variants
in MT-ATP6 that have been associated with MLASA.
Patient 2 (P2) WES study evidenced two new compound heterozygous variants in
YARS2 gene, c.314delG which creates a premature stop codon in the amino acid 109, and
a single nucleotide change in the exon 5 c.1391T>C which predicts the substitution of
isoleucine to threonine at position 464 of YARS2 protein. These variants are located in
the catalytic domain and in the S4-like region of YARS2 protein. As shown in Figure 1,
pathogenic variants in YARS2 have been found distributed along YARS2 protein, including
catalytic domain and S4-like regions. Missense, nonsense, frameshift and splicing variants
have been described as pathogenic variants in YARS2 gene [8,11–17]. Here we investigate
the molecular effects of these two novel YARS2 variants in fibroblasts of the surviving
brother (P1) and found a marked decrease of YARS2 mRNA levels attributed to nonsense-
mediated mRNA decay (NMD) produced by the c.314delG YARS2 variant. Mitochondrial
protein translation was clearly reduced as OXPHOS function in P1 fibroblasts further
translated into deficient overall cell health and growth and these results cannot be attributed
to mtDNA deletion in P1 fibroblasts. Consequently, both variants can be classified as
“pathogenic” following ACMG guidelines (achieving PS3 rule). These variants were
responsible for a phenotype characterized by late-onset MLASA, herein accompanied
by pancreatic insufficiency, which defines Pearson’s syndrome [24]. However, Pearson’s
syndrome has classically not been associated to any point mutation and has been exclusively
associated with single large scale deletion in mtDNA of unknown origin; it has also been
widely described as an infant-onset and severe disease progressing to early death or to the
development of Kearns-Sayre syndrome [27–29]. However, Gustafson et al. have recently
described and suggested that the variant p.(Glu27Lys) in SSBP1 gene can interfere with
mtDNA replication and precipitate the introduction of large scale mtDNA deletions with
clinical manifestations across the clinical spectrum of Pearson, Kearns-Sayre and Leigh
syndromes [27].
The most common ethnicity where YARS2 pathogenic variants are found is in Cau-
casian Americans, followed by Lebanese population, where four subjects have been re-
ported [13]. A Scottish founder mutation has been recently reported, with four other
cases [12]. Interestingly, before that herein reported, only one patient was from Spanish
ethnicity.
Remarkably, most patients with MLASA2 syndrome have an early presentation of
disease, and only three cases of adult onset and one asymptomatic carrier of YARS2
mutation have been reported to date, such as those herein included. From the clinical point
of view, there were only two cases in the literature describing intermittent diarrhea, but not
other data suggesting pancreatic insufficiency has been described before the siblings herein
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reported [12,13]. Lactic acidosis was present in 15 cases and myopathy in 15, without
coexisting in all cases from a total of 17 patients. While sideroblastic anemia may be the
symptom that points toward the diagnosis in MLASA syndrome, it is not present in all
patients, and the severity widely varies among subjects. Moreover, in some cases it may
disappear spontaneously or fluctuate between transfusion dependent crisis and stable
periods, apparently without correlating with the rate of patient survival.
As for the 55 previous reports of patients with Pearson’s syndrome, anemia was
present in most cases, decreasing in case of survival, when multisystem involvement
became prominent [28]. Therefore, the siblings described in this paper, harboring YARS2
variants, present a phenotype that was clinically diagnosed as Pearson’s syndrome with
an unusual benign course that, with the advent of NGS, has been finally diagnosed as
MLASA2. Consequently, the concomitant presence of pancreatic dysfunction will need
deeper investigation in these syndromes and may reveal a common phenotype that has
been ignored to date. Our results, along the same line as others, suggest that MLASA may
be only one of the clinical presentations of YARS2 pathogenic variants, and that some other
syndromic causes of unknown origin or with incompletely described molecular pathogenic
routes of sideroblastic anemia could also be associated to pathogenic variants in this
gene [12]. Understanding the molecular mechanisms underlying the heterogeneity of these
disorders is of great importance as a first step towards developing more effective diagnostic
algorithms and to discover new therapeutic targets to cure or prevent the progression of
the disease.
5. Conclusions
As far as we know, pancreatic dysfunction has not been previously related to pathogenic
variants in YARS2 gene. The newly identified missense variant c.1391T>C, p.(lle464Thr)
and the premature stop codon c.314delG (p.(Gly105Alafs*4)) variant in YARS2 gene are
responsible for a distinct phenotype of mitochondrial disease associating MLASA and
pancreatic insufficiency. Therefore, the present findings open the doors to evaluate YARS2
deficits in heterogeneous forms of disease in association to isolated sideroblastic anemia,
atypical presentations of MLASA [13] and even in other mitochondrial myopathies of
unknown origin.
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